Details for New Drug Application (NDA): 008319
✉ Email this page to a colleague
NDA 008319 describes BUTAZOLIDIN, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the BUTAZOLIDIN profile page.
The generic ingredient in BUTAZOLIDIN is phenylbutazone. There are nine drug master file entries for this compound. Additional details are available on the phenylbutazone profile page.
The generic ingredient in BUTAZOLIDIN is phenylbutazone. There are nine drug master file entries for this compound. Additional details are available on the phenylbutazone profile page.
Summary for 008319
| Tradename: | BUTAZOLIDIN |
| Applicant: | Novartis |
| Ingredient: | phenylbutazone |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 008319
Profile for product number 008
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 009
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 100MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
